Market›Health Care›Biotechnology›Biotechnology
MESOBLAST LTD ADR

MESO

$15.51Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$1.87B
MVM
+$39.9M
TD Variance
0.323

Every news event mapped to its market reaction — 48 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2024-12-18+37.0%legalSeeking AlphaMesoblast rises 13% as FDA approves graft-versus-host disease therapy
2024-12-18+37.0%newsSeeking AlphaMesoblast to join Nasdaq Biotechnology Index
2024-12-19+18.6%newsSeeking AlphaMesoblast Finally Gets Its Approval In GVHD: Where Now?
2025-08-29-16.4%earningsSeeking AlphaMesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
2025-08-29-16.4%earningsSeeking AlphaMesoblast Limited 2025 Q4 - Results - Earnings Call Presentation
2026-02-27-13.8%earningsSeeking AlphaMesoblast misses H1 estimates
2026-02-27-13.8%earningsSeeking AlphaMesoblast Limited (MESO) Q2 2026 Earnings Call Transcript
2025-10-07+13.8%newsSeeking AlphaMesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case
2024-09-30+9.3%newsSeeking AlphaMesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential
2024-09-30+9.3%expansionSeeking AlphaMesoblast to issue $50M convertible notes for product launch
2024-09-30+9.3%newsSeeking AlphaMesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
2026-04-15+9.1%legalMT NewswiresSector Update: Health Care Stocks Rise Pre-Bell Wednesday
2026-04-15+9.1%legalMT NewswiresSector Update: Health Care
2026-04-15+9.1%newsMT NewswiresMesoblast Buys License to Chimeric Antigen Receptor Technology Platform; Shares Up Pre-Bell
2026-04-15+9.1%M&AGlobeNewswireMesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
2026-04-15+9.1%M&ASeeking AlphaMesoblast gains on licensing deal for CAR technology platform
2026-04-07-9.0%newsSeeking AlphaMesoblast drops after Ryoncil sales data for March quarter
2026-04-07-9.0%newsSeeking AlphaMesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
2025-05-05-8.3%newsSeeking AlphaBullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials
2026-04-09+7.2%legalSimply Wall St.Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?
2026-04-09+7.2%newsSeeking AlphaMesoblast Limited (MESO) Discusses Cellular Medicine Platforms and Innovations at R&D Day Transcript
2026-01-09-6.9%newsSeeking AlphaMesoblast rises as Ryoncil sales climb 60% in December quarter
2024-10-06-6.7%newsSeeking AlphaHedge funds pile into healthcare stocks amid dip, Goldman Sachs says
2024-08-29+4.8%earningsSeeking AlphaMesoblast GAAP EPS of -$0.09 beats by $0.63, revenue of $5.9M misses by $1.71M
2026-04-13-4.8%newsSeeking AlphaMesoblast Limited: A Risk/Reward Story
2026-02-11-4.5%newsSeeking AlphaMesoblast: Real-World Data Validates The Bull Case For Ryoncil
2025-12-11-4.3%newsthebull.com.auMesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
2025-10-17-4.0%newsBenzingaBitfarms, Standard Lithium, Terawulf And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
2025-01-31+4.0%earningsSeeking AlphaMesoblast reports Q2 results
2026-03-13-3.4%newsAD HOC NEWSMesoblast Ltd Stock (ISIN: AU000000MSB8) Faces Pressure as Director Buys Signal Confidence Amid Anal - AD HOC NEWS
2026-03-18+3.4%newsStock TitanPhilip Krause details Mesoblast (NASDAQ: MESO) share and option holdings - Stock Titan
2026-04-08+3.1%analystSeeking AlphaWhy Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
2026-04-08+3.1%legalSeeking AlphaMesoblast gains as FDA clears study to test Ryoncil in Duchenne
2024-02-12+3.1%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2026-04-12-3.0%newsSimply Wall St.Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases
2025-11-17+2.6%executiveSeeking AlphaMesoblast appoints James M. OBrien as US-based CFO
2026-02-25+2.1%earningsSeeking AlphaMesoblast 1H 2026 Earnings Preview
2025-10-06-1.7%newsBenzingaQuantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
2024-12-31-1.4%newsSeeking AlphaMesoblast After Approval: Stock Is Buoyant Now, But Unpredictable Overall
2025-07-07-1.4%analystSeeking AlphaMesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade)
2026-04-19+1.1%newsInsider MonkeyMesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why
2026-04-20-0.8%newsInsider MonkeyWhy Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in
2025-07-01-0.7%legalSeeking AlphaMesoblast, FDA agree on marketing application for cell therapy
2025-02-28-0.6%earningsSeeking AlphaMesoblast Limited (MESO) Q2 2025 Earnings Call Transcript
2025-02-28-0.6%earningsSeeking AlphaMesoblast Limited 2024 Q4 - Results - Earnings Call Presentation
2025-02-15+0.3%newsSeeking AlphaMesoblast: Ryoncil Approval Overshadowed By Commercial Hurdles
2026-04-10+0.1%legalMT NewswiresMesoblast Gets US FDA Clearance to Proceed to Registrational Trial for Ryoncil in Duchenne Muscular Dystrophy
2026-04-10+0.1%legalGlobeNewswireMesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
tickerdossier.comtickerdossier.substack.com